Scleroderma is an autoimmune connective tissue and rheumatic disease that is caused by the immune system attacking the connective tissue under the skin and around internal organs and blood vessels, which can lead to scarring and thickening of the tissue in these areas. It’s a progress disease that can produce symptoms and complications which varies widely in people with scleroderma, ranging from mild to severe.
About Our Program
The Michigan Medicine Scleroderma Program, established in 2004 in the Division of Rheumatology, is a multidisciplinary group of researchers and health care providers dedicated to advancing research and improving care for patients with scleroderma and its related complications. Our team consists of specialists from many disciplines, including rheumatology, pulmonary, cardiology, gastroenterology, infectious diseases, dermatology, physical medicine & rehabilitation, and plastic surgery. Meet the team.
Our researchers conduct a broad range of basic, translational, and observational studies, and clinical trials to increase our understanding of the mechanisms behind scleroderma, and to develop improved diagnostic and targeted treatment options.
Basic and Translational Studies
Clinical Trials and Observational Studies
Clinical trials to evaluate interventions (a drug, device, or procedure) and observational studies to observe a patient’s disease, symptoms, and health over time without introducing an intervention are being conducted by our researchers in various and relevant areas. Learn more.
Please visit Patient Care to learn about scleroderma, including classifications, symptoms, and complications, how to make an appointment, and more.
Support Our Work
To make a gift to support our research, please visit the Scleroderma Cure Fund.